Research provides framework for developing Ebola virus therapeutic under animal rule

The US Army Medical Research Institute of Infectious Diseases (USAMRIID) announced that, for the first time, the US Food and Drug Administration (FDA) has provided formal regulatory agreement for use of an animal model to support development of a drug candidate, remdesivir, for treating deadly Ebola virus infections.

MSF begins enrolling patients in clinical trial of potential Ebola treatments

Doctors Without Borders/Médecins Sans Frontières (MSF) will participate in an ongoing randomized controlled trial of four potential Ebola treatments in North Kivu, Democratic Republic of Congo, in collaboration with the Ministry of Health, the international medical humanitarian organization said Tuesday.

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

mAb114 was well tolerated, showed linear pharmacokinetics, and was easily and rapidly infused, making it an attractive and deployable option for treatment in outbreak settings.

Ebola: Clinical management of Ebola virus disease

This intermediate level course is for clinicians caring for patients with suspected or confirmed Ebola virus disease. Modules provide information on screening and triage, infection prevention and control, laboratory diagnostics, organization of the Ebola Treatment Centre (ETC), clinical care of patients in the ETC, and investigational therapeutic agents.